Back to top
more

Elevance Health, Inc. (ELV)

(Delayed Data from NYSE)

$417.86 USD

417.86
1,931,027

+3.85 (0.93%)

Updated Nov 4, 2024 04:00 PM ET

After-Market: $417.84 -0.02 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 250)

Industry: Medical Services

Zacks News

Zacks Industry Outlook Highlights Elevance Health, Cencora and ICON

Elevance Health, Cencora and ICON are part of the Zacks Industry Outlook article.

Urmimala Biswas headshot

3 Medical Services Stocks to Buy as Industry Trends Improve

The Zacks Medical - Services industry is growing on digital healthcare adoption. ELV, COR and ICLR are set to gain the most. However, staffing shortages continue to disrupt the growth trend.

Brokers Suggest Investing in Elevance Health (ELV): Read This Before Placing a Bet

Based on the average brokerage recommendation (ABR), Elevance Health (ELV) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Elevance Health (ELV) Bolsters CarelonRx With Paragon Buyout

The infusion services from Paragon Healthcare are expected to complement Elevance Health's (ELV) suite of pharmacy services.

Stereotaxis (STXS) Seeks Clearance for MAGiC Catheter

Stereotaxis (STXS) announces the regulatory submissions of its MAGiC catheter in Europe and the United States, which are intended for use in minimally invasive cardiac ablation treatments.

Silk Road Medical's (SILK) New Stent Expands Its TCAR Portfolio

Silk Road Medical (SILK) announces the launch of its Tapered ENROUTE Transcarotid Stent System to hospitals in the United States.

ELV or GDRX: Which Is the Better Value Stock Right Now?

ELV vs. GDRX: Which Stock Is the Better Value Option?

Elevance Health (ELV) Dips More Than Broader Market: What You Should Know

In the closing of the recent trading day, Elevance Health (ELV) stood at $498.35, denoting a -1.19% change from the preceding trading day.

BD (BDX) Initiates IDE Study to Aid Treatment of Artery Disease

BD (BDX) commences the enrollment of the first patient in the IDE study for the assessment of the company's Vascular Covered Stent for the treatment of Peripheral Arterial Disease.

Philips (PHG), SyntheticMR Unite to Aid Brain Diagnosing Space

Philips (PHG) and SyntheticMR collaborate to launch of Smart Quant Neuro 3D, which is likely to boost the brain diagnosing field by providing automatic and precise 3D segmentation of brain tissues.

Philips' (PHG) CT 5300 to Boost Diagnostic Capabilities

Philips (PHG) announces its latest innovation, Philips CT 5300, which leverages the power of AI at every stage in CT scanner operation to enhance productivity and diagnostic capabilities.

Profound Medical (PROF), Siemens Unite to Treat Prostate Cancer

Profound Medical (PROF) collaborates with Siemens to boost prostate cancer treatment procedures by combining their technologies.

Veeva Systems (VEEV) Q4 Earnings Surpass Estimates, Margins Up

Veeva Systems' (VEEV) fiscal Q4 results reflect impressive performances by both segments.

Veradigm (MDRX) to Acquire AI Service Provider ScienceIO

Veradigm (MDRX) is set to acquire ScienceIO to benefit its Provider, Payer and Life Sciences businesses, offering highly differentiated and advanced products to its customers.

Cooper Companies (COO) Q1 Earnings Top, '24 Outlook Raised

Cooper Companies' (COO) first-quarter fiscal 2024 revenues reflect a solid segmental performance with improved adjusted earnings amid rising expenses.

Inari Medical (NARI) Q4 Earnings Improve Y/Y, Gross Margin Down

Inari Medical's (NARI) fourth-quarter earnings miss, while sales match estimates. Gross margin improves while the company incurs losses at the operating level.

Merit Medical (MMSI) Q4 Earnings Top Estimates, Gross Margin Up

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the fourth quarter.

DENTSPLY SIRONA (XRAY) Q4 Earnings Beat Estimates, Sales Up Y/Y

DENTSPLY SIRONA's (XRAY) Q4 revenues improve year over year. Challenging macro headwinds linger.

Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw

Nevro's (NVRO) SI joint fusion device, Nevro1, gets FDA clearance for the use of a lateral screw NevroFix.

Philips' (PHG) New Innovation to Boost Neurovascular Diagnosis

Philips (PHG) announces its latest Azurion neuro biplane system, which aims to improve the diagnosis of stroke and major neurovascular diseases. The system is designed for superior patient care.

Patterson Companies (PDCO) Misses on Q3 Earnings, Lowers EPS View

Patterson Companies' (PDCO) third-quarter fiscal 2024 results reflect an improvement in Dental Consumable sales, offset by lower Dental Equipment sales. Animal health sales appear weak.

Inogen (INGN) Q4 Earnings Miss Estimates, Gross Margin Improves

Inogen's (INGN) fourth-quarter earnings and revenues miss their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.

Masimo (MASI) Q4 Earnings Beat Estimates, Margins Decline

Despite strength in the Hearables category, Masimo's (MASI) overall fourth-quarter results reflect soft performances.

OPKO Health's (OPK) Q4 Earnings Match Estimates, Revenues Top

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall fourth-quarter results reflect soft performances.

GE HealthCare (GEHC), Biofourmis Partner to Boost At-Home Care

GE HealthCare (GEHC) collaborates with Biofourmis to facilitate the patient's journey throughout the healthcare system and make the transition from hospital to home care easier.